140 related articles for article (PubMed ID: 2300507)
1. Problems associated with the administration of intraperitoneal therapy using the Port-A-Cath system.
Almadrones L; Yerys C
Oncol Nurs Forum; 1990; 17(1):75-80. PubMed ID: 2300507
[TBL] [Abstract][Full Text] [Related]
2. Complications associated with intraperitoneal chemotherapy catheters.
Makhija S; Leitao M; Sabbatini P; Bellin N; Almadrones L; Leon L; Spriggs DR; Barakat R
Gynecol Oncol; 2001 Apr; 81(1):77-81. PubMed ID: 11277654
[TBL] [Abstract][Full Text] [Related]
3. Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: a single institution's experience.
Ivy JJ; Geller M; Pierson SM; Jonson AL; Argenta PA
Gynecol Oncol; 2009 Sep; 114(3):420-3. PubMed ID: 19560189
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal access via direct puncture is an alternative way to deliver intraperitoneal chemotherapy in ovarian, fallopian tube and primary peritoneal cancer.
Lan C; Li Y; Liu J
Gynecol Oncol; 2009 Jul; 114(1):42-7. PubMed ID: 19398124
[TBL] [Abstract][Full Text] [Related]
5. Experience with implanted subcutaneous ports for intraperitoneal chemotherapy in ovarian cancer.
Malmström H; Carstensen J; Simonsen E
Gynecol Oncol; 1994 Jul; 54(1):27-34. PubMed ID: 8020835
[TBL] [Abstract][Full Text] [Related]
6. It's not just for laparoscopy anymore: use of insufflation under ultrasound and fluoroscopic guidance by Interventional Radiologists for percutaneous placement of intraperitoneal chemotherapy catheters.
Henretta MS; Anderson CL; Angle JF; Duska LR
Gynecol Oncol; 2011 Nov; 123(2):342-5. PubMed ID: 21840583
[TBL] [Abstract][Full Text] [Related]
7. Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies.
Kehoe SM; Williams NL; Yakubu R; Levine DA; Chi DS; Sabbatini PJ; Aghajanian CA; Barakat RR; Abu-Rustum NR
Gynecol Oncol; 2009 May; 113(2):228-32. PubMed ID: 19254808
[TBL] [Abstract][Full Text] [Related]
8. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
[TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
Walker JL; Armstrong DK; Huang HQ; Fowler J; Webster K; Burger RA; Clarke-Pearson D
Gynecol Oncol; 2006 Jan; 100(1):27-32. PubMed ID: 16368440
[TBL] [Abstract][Full Text] [Related]
10. Complications relating to intraperitoneal administration of cisplatin or carboplatin for ovarian carcinoma.
Sakuragi N; Nakajima A; Nomura E; Noro N; Yamada H; Yamamoto R; Fujimoto S
Gynecol Oncol; 2000 Dec; 79(3):420-3. PubMed ID: 11104613
[TBL] [Abstract][Full Text] [Related]
11. Laparoscopic intraperitoneal port placement for optimally cytoreduced advanced ovarian cancer.
Janco JM; Hacker MR; Konstantinopoulos PA; Cannistra SA; Awtrey CS
J Minim Invasive Gynecol; 2011; 18(5):629-33. PubMed ID: 21803662
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates.
Landrum LM; Gold MA; Moore KN; Myers TK; McMeekin DS; Walker JL
Gynecol Oncol; 2008 Feb; 108(2):342-7. PubMed ID: 17988721
[TBL] [Abstract][Full Text] [Related]
14. Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer.
Black D; Levine DA; Nicoll L; Chou JF; Iasonos A; Brown CL; Sonoda Y; Chi DS; Leitao MM; Abu-Rustum NR; Ferguson SE; Barakat RR
Gynecol Oncol; 2008 Apr; 109(1):39-42. PubMed ID: 18234300
[TBL] [Abstract][Full Text] [Related]
15. Therapy of infections related to intraperitoneal catheters in patients with ovarian cancer.
Meunier F; van der Auwera P; Aoun M; Piccart M; Sculier JP
Scand J Infect Dis Suppl; 1990; 72():26-8. PubMed ID: 2151063
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
[TBL] [Abstract][Full Text] [Related]
17. [The value of a Tenckhoff catheter in ovarian cancer].
Kato N; Arakawa A; Yasui Y; Suzumori K; Suzumori K; Yagami Y
Gan To Kagaku Ryoho; 1991 May; 18(6):1025-30. PubMed ID: 2029187
[TBL] [Abstract][Full Text] [Related]
18. The Groshong catheter as an intraperitoneal access device in the treatment of ovarian cancer patients.
Naumann RW; Alvarez RD; Partridge EE; Kilgore LC; Austin JM
Gynecol Oncol; 1993 Sep; 50(3):291-3. PubMed ID: 8406189
[TBL] [Abstract][Full Text] [Related]
19. [Intraperitoneal chemotherapy using CBDCA for malignant gynecological tumors].
Shimizu A; Kimura T; Funatsu M; Hada Y; Tamura K; Taguchi A; Miyakawa Z; Notake Y
Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1738-41. PubMed ID: 1530345
[TBL] [Abstract][Full Text] [Related]
20. Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications.
Lesnock JL; Richard SD; Zorn KK; Krivak TC; Beriwal S; Sukumvanich P; McBee WC; Kelley JL; Edwards RP
Gynecol Oncol; 2010 Mar; 116(3):345-50. PubMed ID: 19959211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
